Stocktoria
Bicara Therapeutics Inc. BCAX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2024-09-13
Chart by TradingView
2/9
Piotroski F — financial health
15.11
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Financials | |||
| Operating income | -$155.6M | -$82.4M | -$39.9M |
| Net income | -$137.9M | -$68.0M | -$52.0M |
| Operating cash flow | -$106.8M | -$74.8M | -$45.6M |
| Free cash flow | -$107.1M | -$74.8M | -$46.2M |
| Total assets | $431.0M | $510.0M | $234.0M |
| Total liabilities | $29.5M | $18.1M | $15.5M |
| Shareholders' equity | $401.5M | $491.9M | -$148.8M |
| Ratios | |||
| Return on assets | -32.0% | -13.3% | -22.2% |
| Return on equity | -34.4% | -13.8% | 34.9% |
| Current ratio | 14.58 | 27.93 | 15.32 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 15.11 (safe)
- Working capital / assets 0.912
- Retained earnings / assets -0.833
- EBIT / assets -0.361
- Equity / liabilities 13.589
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0002023658 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.